What is B. Riley’s Estimate for InfuSystem Q1 Earnings?

InfuSystem Holdings, Inc. (NYSE:INFU) – Research analysts at B. Riley issued their Q1 2026 EPS estimates for shares of InfuSystem in a report released on Thursday, May 8th. B. Riley analyst A. Schock expects that the company will post earnings of $0.04 per share for the quarter. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for InfuSystem’s current full-year earnings is $0.15 per share. B. Riley also issued estimates for InfuSystem’s Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.09 EPS and Q4 2026 earnings at $0.11 EPS.

Several other equities research analysts have also commented on the stock. Sidoti upgraded shares of InfuSystem to a “strong-buy” rating in a research note on Tuesday, March 18th. StockNews.com upgraded InfuSystem from a “buy” rating to a “strong-buy” rating in a report on Friday, March 14th.

InfuSystem Stock Up 4.9%

INFU opened at $5.75 on Monday. InfuSystem has a fifty-two week low of $4.61 and a fifty-two week high of $9.97. The firm has a market capitalization of $120.84 million, a P/E ratio of 95.85 and a beta of 1.73. The company’s 50-day moving average is $5.26 and its 200 day moving average is $7.14. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.98 and a quick ratio of 1.59.

Hedge Funds Weigh In On InfuSystem

Institutional investors have recently added to or reduced their stakes in the stock. American Century Companies Inc. bought a new stake in InfuSystem in the first quarter worth about $256,000. Russell Investments Group Ltd. raised its holdings in shares of InfuSystem by 13.1% in the 1st quarter. Russell Investments Group Ltd. now owns 437,891 shares of the company’s stock worth $2,356,000 after purchasing an additional 50,877 shares during the period. Nuveen LLC purchased a new position in InfuSystem in the first quarter valued at approximately $465,000. Virtu Financial LLC bought a new position in InfuSystem during the first quarter valued at $86,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in InfuSystem by 107.7% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 50,218 shares of the company’s stock worth $270,000 after buying an additional 26,040 shares during the last quarter. Institutional investors own 71.13% of the company’s stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.